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Introduction
Endovascular aneurysm repair (EVAR) offers a shortterm benefit over open repair for the management of large abdominal aortic aneurysms (AAA). 1, 2 However, data from registries-eg, EUROSTAR (European Collaborators Registry on Stent-graft Techniques for AAA Repair) and RETA (Registry for Endovascular Treatment of Aneurysms) 3, 4 -indicate the need for close surveillance of endografts over many years, since complications arise in 25-40% of patients who often need additional interventions or conversion to open surgery. 5, 6 As the technology of EVAR develops, graft durability should improve and the number of complications reported should fall. 7 Trials with a similar protocol to EVAR trial 1 are underway in the Netherlands (DREAM), France (ACE), and the USA (OVER). 8 The most advanced of these, the Dutch DREAM trial, 2, 9 has focused on short-term combined mortality and morbidity outcomes, and preliminary results suggest that EVAR is not associated with an enduring improvement in healthrelated quality of life (HRQL) at 12 months. 9 Other studies 10 suggest that EVAR is more expensive than open repair.
Our aim was to assess longterm survival, generalisability, graft durability, HRQL, and hospital costs associated with both EVAR and open repair. Midterm results are presented.
Methods
The detailed methods for EVAR trial 1 have been published. 11 Briefly, recruitment into the trial began on Sept 1, 1999, with 13 eligible UK hospitals. We regarded hospitals as eligible when they had completed 20 EVAR procedures and submitted the data to RETA. 4 During the subsequent 4 years the number of hospitals that had sufficient experience with EVAR increased to 41, though only 34 of these had entered patients into EVAR trial 1 by the end of planned recruitment on Dec 31, 2003. Trained trial coordinators at every centre were responsible for recruitment of patients and data collection. Data were collated centrally and confidentially at the main trial office based at Charing Cross Hospital, Imperial College, London.
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Summary
Background Although endovascular aneurysm repair (EVAR) has a lower 30-day operative mortality than open repair, the long-term results of EVAR are uncertain. We instigated EVAR trial 1 to compare these two treatments in terms of mortality, durability, health-related quality of life (HRQL), and costs for patients with large abdominal aortic aneurysm (AAA).
Methods
We did a randomised controlled trial of 1082 patients aged 60 years or older who had aneurysms of at least 5·5 cm in diameter and who had been referred to one of 34 hospitals proficient in the EVAR technique. We assigned patients who were anatomically suitable for EVAR and fit for an open repair to EVAR (n=543) or open repair (n=539). Our primary endpoint was all-cause mortality, with secondary endpoints of aneurysm-related mortality, HRQL, postoperative complications, and hospital costs. Analyses were by intention to treat. Interpretation Compared with open repair, EVAR offers no advantage with respect to all-cause mortality and HRQL, is more expensive, and leads to a greater number of complications and reinterventions. However, it does result in a 3% better aneurysm-related survival. The continuing need for interventions mandates ongoing surveillance and longer follow-up of EVAR for detailed cost-effectiveness assessment.
Patients
During recruitment, we asked every centre to register all consecutive male and female patients into the EVAR study if they were aged 60 years or older and had an aneurysm that was suspected to measure at least 5·5 cm in diameter in any plane, according to a computed tomography (CT) scan. An interventional radiologist assessed patients for aneurysm diameter and anatomical suitability for EVAR. Patients who were suitable were assessed locally for fitness-ie, anaesthetically and medically well enough-for elective (non-emergency) open repair; we provided guidelines for cardiac, respiratory, and renal status. Patients judged fit for both procedures were offered entry into EVAR trial 1. Patients who were unsuitable for EVAR were offered open repair or surveillance. Patients considered unfit for the open procedure were offered entry into EVAR trial 2.
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All patients provided written informed consent, and the study was approved by the North-West Multicentre Research Ethics Committee.
Procedures
The trial manager, independently of the participating centres, undertook randomisation to EVAR or open repair, using a one-to-one ratio in randomly sized permuted blocks stratified by centre. We encouraged centres to do surgery within 30 days of randomisation. All patients were flagged for mortality at the Office for National Statistics and all death certificates were reviewed by an endpoint committee, without knowledge of randomisation, to agree cause of death and assign an International Classification of Diseases (ICD) code. 13 Aneurysm-related mortality was defined as all deaths within 30 days of any surgery for AAA unless overruled by post-mortem findings or if a separate procedure (unrelated to the aneurysm) took place between aneurysm repair and death and was attributed as the cause of death. Deaths for which the underlying cause was attributed to ICD10 codes I713-19 were also classified as aneurysm related. We categorised deaths that arose within 30 days of any aneurysm surgery as procedure-related. We also recorded late complications of aneurysm repair (more than 30 days after operation), such as aortoduodenal fistula or aortic rupture after endografting, as procedure-related aneurysm deaths.
After aneurysm repair, we saw patients at 1, 3, and 12 months, and yearly thereafter. To monitor graft durability, we collected CT scan data yearly for all patients in both treatment groups. Patients treated with EVAR had additional CT scans at 1 and 3 months after the procedure. Follow-up for HRQL included completion of the Short Form 36 (SF36) 14 and EuroQol 5-D (EQ5D) weighted index score 15 at 1, 3, and 12 months after surgery. For the main hospital admission, we obtained data on key resource use, including length of hospital stay, duration of procedure, type of device or graft, and the resource implications of complications. We also obtained data on adverse events, such as myocardial infarction, stroke, amputation, or the need for chronic renal dialysis. We recorded postoperative complications relating to the aneurysm and hospital admissions (with associated resource use) for secondary interventions, but not details about use of community-based health services, pharmaceuticals, and hospital stay for reasons other than those listed above. We did not include costs associated with diagnostic tests or imaging before declaration of suitability for EVAR. An independent data monitoring and ethics committee monitored data during the course of the trial. One interim analysis was done in May, 2003, after the first 100 deaths had occurred, but stopping rules did not need to be implemented.
Our primary outcome was all-cause mortality, with secondary outcome measures of aneurysm-related mortality, incidence of postoperative complications of aneurysm repair and secondary interventions, HRQL, and hospital costs. 
Statistical analysis
Our recruitment target was 900 patients. With an average follow-up of 3·3 years, this number of patients would yield 80% power to detect at the 5% significance level a reduction in all-cause mortality from 7·5% to 5% per year (174 deaths in total). 11 All analyses were done in accordance with a predefined analysis plan, which was agreed before any outcome data were made available. Patients randomised up to Dec 31, 2003, were included and follow-up was truncated on Dec 31, 2004. All primary and secondary endpoints were analysed by intention to treat.
We used Kaplan-Meier methods to construct survival curves for all-cause and aneurysm-related mortality, and Cox regression to calculate hazard ratios with 95% CIs; hazard ratios of less than 1 favoured the EVAR group. We calculated crude hazard ratios and adjusted them first for age, sex, forced expiratory volume in 1 sec (FEV 1 ), AAA diameter, log (creatinine), and statin use at baseline, with secondary adjustments for body-mass index (BMI), smoking status, systolic blood pressure, and serum cholesterol concentrations. We selected primary covariates because they are predictors of survival after an open AAA repair, 16 and the secondary covariates because they are known prognostic indicators for cardiovascular mortality. 17, 18 We used the missing indicator method-including a dummy variable for every missing baseline covariate-for the adjusted analyses. 19 Patients lost to follow-up were included in all intention-to-treat analyses but censored at their last date known to be alive. We assessed interactions for age, sex, aneurysm diameter, and creatinine, with the last variable dichotomised at its median value.
We established classifications for graft-related complications at the start of the trial, according to the modified guidelines of White and May. 20 In some instances, patients had more than one type of graft complication, but for the purposes of analysis we categorised patients by their most serious complication-for example, if a patient had a type 1 endoleak followed for a period of time, which then deteriorated to graft migration, we classified the patient under migration. Thus, the number of complications is greater than the number of patients. We analysed time from randomisation to first complication and to first secondary intervention with Kaplan-Meier methods, and used Cox regression to calculate hazard ratios between the two randomised groups. We censored patients who did not have a complication or secondary intervention at death, loss to follow-up, or on Dec 31, 2004.
We assessed HRQL after surgery with the EQ5D and SF36 questionnaires, and classified the results into three timepoints from randomisation: 0-3 months, 3-12 months, and 12-24 months. HRQL was summarised by three outcomes: the EQ5D weighted index score and the SF36 physical and mental component summary scores. We did a secondary HRQL analysis at 1, 3, and 12 months after the operation. Differences were adjusted for baseline scores with analysis of covariance.
We calculated hospital costs up to 4 years from randomisation. We based costs on resource-use data collected in the trial case record forms and in questionnaires sent to 41 trial centres (21 completed forms returned by May, 2004), which sought information on centre-specific resource use, such as staffing of procedures, equipment, and consumables used, and routine outpatient follow-up outside of the trial. We costed resource use with local unit costs taken from the questionnaire when possible, or otherwise with national unit costs from routine UK National Health Service (NHS) sources, for the financial year 2003-04· [21] [22] [23] We used the method of inverse weighting to estimate mean total costs in each group, and the www.thelancet. difference in cost, taking into account censoring. 24 We used bootstrap methods to obtain the standard error for the difference in mean costs. 25 We used mean imputation, conditional on treatment group, to impute missing resource-use data. We discounted costs by 3·5% per year.
26
Role of the funding source
The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Results
Between September, 1999, and December, 2003, 34 centres registered 4799 patients for consideration for entry into either EVAR trial 1 or 2. Figure 1 shows the trial profile. 1423 patients were eligible; 341 refused to be randomised. Patients who refused were similar to those randomised in terms of their mean age (74 years, SD 7) and the proportion who were men (89%, n=302), but their aneurysm diameter was slightly greater (median 64 cm, IQR 5·9-7·0, p=0·02). Table 1 of the first EVAR report 1 shows the baseline characteristics of the two randomised groups, which were similar: mean age 74 years (SD 6), 91% (n=983) men, and median aneurysm diameter 6·2 cm (IQR 5·8-7·0). The median time from randomisation to surgery was 43 days (28- . 90% (n=481) of these grafts were bifurcated and the remainder were aortouni-iliac.
By Dec 31, 2004, 100% of patients had been followed up for 1 year, 70% for 2 years, 47% for 3 years, and 24% for 4 years. There were 209 deaths; 53 aneurysmrelated (table 1) and 68 from other cardiovascular disorders (table 2). All-cause mortality at 4 years after randomisation was similar in the two groups (table 1, figure 2 ). However, there was a persistent difference in aneurysm-related mortality (table 1, figure 2 ). There were no significant interactions, for either all-cause or aneurysm-related mortality, with age, sex, aneurysm diameter, or creatinine concentration (all pϾ0·2).
In a post-hoc analysis, we divided the follow-up into the first 6 months after randomisation and the period after 6 months. The hazard ratios for aneurysm-related mortality, comparing the EVAR and open repair groups, were 0·42 (95% CI 0·21-0·82) and 1·15 (0·39-3·41) in the two periods, respectively, the latter having a wide CI because of the few deaths included. The corresponding hazard ratios for total mortality were 0·55 (0·33-0·93) and 1·10 (0·80-1·52).
Analysis by intention to treat for the time from randomisation to first complication and first secondary intervention is shown in figure 3 . During the first 4 years of follow-up, the overall rates of complications and reinterventions seemed to diverge between groups. By 4 years, the proportion of patients with at least one complication after AAA repair was 41% in the EVAR (29) 13 (13) theatre procedure, two more during the primary admission, and eight after initial discharge from hospital. By contrast, complications and reinterventions were rare in open repair patients. At baseline, the EQ5D scores were similar in both groups and to age-matched and sex-matched population norms (table 4) . 27 Although the open repair group had a diminished HRQL at 0-3 months, it had recovered by 3-12 months and at 12-24 months after randomisation there was no difference between the groups (table 4) . Secondary analyses based on time from surgery did not alter these findings (data not shown).
Mean resource use is shown in table 5. The costs per patient of the primary procedure and hospital admission, on an intention-to-treat basis, were higher in the EVAR group than in the open repair group (table 6).
Discussion
Our midterm results for all-cause and aneurysmrelated mortality, together with post-operative complications and reinterventions, HRQL, and hospital Although we priced surveillance in accordance with routine clinical protocols, rather than the more rigorous trial protocol, it added to the increased hospital costs of EVAR versus open repair. We will do a followup analysis when more data are available to ascertain whether the rates of complications and reinterventions will diminish over time, or with newer generations of endografts or different types of graft.
There is no clear suggestion that the need for continued surveillance in the EVAR group has affected HRQL scores. Neither SF36 nor EQ5D identified any strong differences between the groups up to 2 years after randomisation. The deterioration of HRQL early after open repair echoes the findings of the DREAM trial. 9 However, though the DREAM trial reported an improved HRQL (EQ5D) for open repair versus EVAR patients after 6 months, our trial showed no difference between the two groups at either 3-12 or 12-24 months.
Of the patients assessed for eligibility, we considered just over half of those with aneurysms of at least 5·5 cm in diameter anatomically suitable for EVAR. Others 28, 29 have reported similar degrees of suitability for EVAR. Despite its benefit on 30-day operative mortality EVAR cannot, therefore, displace open repair, and the skills of open repair should be maintained in the training of vascular surgeons.
Midterm results show a 3% aneurysm-related survival benefit for EVAR in fit patients, with increased need for reinterventions and constant surveillance, which increase hospital costs. There is no midterm evidence of all-cause mortality or HRQL benefit from EVAR. Therefore, we have begun a detailed longterm costeffectiveness evaluation to contribute to guidelines for the use of EVAR in routine clinical practice. 
